Seer Inc. Receives Fourth Buyout Bid at $2.55/Share — Activist-vs-Management Bidding War Intensifies

Event Analysis

According to Investing.com, shareholders Bradley L. Radoff and Michael Torok — who jointly control approximately 7.7% of Seer, Inc. (NASDAQ: SEER) — have submitted a fourth non-binding buyout proposal at $2.55 per share in cash, plus a contingent value right (CVR) entitling shareholders to 85% of net proceeds from any future asset sale or licensing of Seer's business, including its PrognomiQ subsidiary. The proposal carries no financing contingency and remains open until August 10, 2026.

This is the latest escalation in a compressed bidding sequence: $2.25 (April 13), $2.35 (April 24), $2.40 (May 14), and now $2.55 — each rejected or ignored by Seer's board. Separately, CEO Omid Farokhzad submitted his own management-led buyout at $2.45/share plus two CVRs, which Seer's special committee of independent directors also unanimously rejected. What distinguishes the fourth Radoff-Torok bid is its improved economics: the cash floor is now the highest on the table, and CVR participation has risen from 80% to 85% of net proceeds. The 51% premium to Seer's April 10 unaffected price and 29% premium to its most recent Monday close signal the activist group's conviction that the board is materially undervaluing the company.

The governance dynamic here is a textbook cross-sector acquisition repricing situation: two competing bidder structures (activist shareholders versus management), a resistant board, and an active proxy contest — creating a classic small-cap life-science M&A acquisition wave scenario. For students of acquisition arbitrage, the succession of escalating bids with no deal closure yet suggests the board is either seeking a higher price or exploring a third-party strategic buyer.

What This Means for Traders

This is an idiosyncratic event-driven setup with limited read-through to broader indices. SEER itself is a micro-cap proteomics name, and its weight in the S&P 500 Index or NASDAQ 100 Index is negligible. The trade here is squarely in SEER equity: the arbitrage spread between SEER's current price and the $2.55 cash floor is the primary signal. Traders should also factor in the CVR's option value — 85% of PrognomiQ-linked asset proceeds within 6–12 months post-close — which is difficult to model but represents asymmetric upside if a strategic licensing deal materializes.

The key risk is deal failure: all proposals remain non-binding, the board has rejected every prior bid, and activist-management tension could extend the process indefinitely or trigger litigation. For traders following the broader acquisition-driven stock moves playbook, the pattern of escalating bids is structurally bullish for SEER's floor price — but the absence of a signed definitive agreement means significant binary risk remains. Volatility is likely to stay elevated around any 8-K filings or board responses.

Start Trading on CoinUnited.io

Create Your Free Account → — Trade crypto, stocks, forex, indices, and commodities with up to 2000x leverage and zero fees.